High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84141
Title:
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.
Authors:
Williams, Catherine D; Harrison, C N; Lister, T Andrew; Norton, Andrew J; Blystad, A K; Coiffier, B; Taghipour, G; Schmitz, N; Goldstone, Anthony H
Abstract:
PURPOSE: To assess the outcome of high-dose therapy with autologous stem-cell support in patients with histologic transformation of low-grade follicular non-Hodgkin's lymphoma (NHL) and identify significant prognostic factors, as well as to compare survival of these patients with that of patients with matched low-grade and de novo high- or intermediate-grade NHL undergoing the same procedure. PATIENTS AND METHODS: Fifty patients with transformed low-grade NHL have been reported to the European Bone Marrow Transplant registry. Outcome from high-dose therapy and significant prognostic factors were analyzed. Their survival was also compared with that of 200 patients with matched low-grade NHL and 200 patients with matched de novo high- or intermediate-grade NHL by a case-matched analysis. RESULTS: The procedure-related death rate among the 50 transformed NHL patients was 18%. Overall survival (OS) and progression-free survival (PFS) rates were 51% and 30% at 5 years, respectively. Median PFS time was 13 months. Raised lactate dehydrogenase levels at transformation (P =.0031) was identified as the only adverse significant predictor of PFS on multivariate analysis. A subgroup of patients with residual chemosensitive disease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5 years of 69%. A comparison with matched patients with low-grade disease and with de novo high- or intermediate-grade lymphoma showed no significant difference in OS (P =.939 and P =.438, respectively). CONCLUSION: Patients with chemosensitive transformed lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.
Affiliation:
Department of Hematology, University College Hospital, London, United Kingdom. catherine.williams@christie-tr.nwest.nhs.uk
Citation:
High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. 2001, 19 (3):727-35 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
1-Feb-2001
URI:
http://hdl.handle.net/10541/84141
PubMed ID:
11157024
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorWilliams, Catherine Den
dc.contributor.authorHarrison, C Nen
dc.contributor.authorLister, T Andrewen
dc.contributor.authorNorton, Andrew Jen
dc.contributor.authorBlystad, A Ken
dc.contributor.authorCoiffier, Ben
dc.contributor.authorTaghipour, Gen
dc.contributor.authorSchmitz, Nen
dc.contributor.authorGoldstone, Anthony Hen
dc.date.accessioned2009-10-13T09:06:31Z-
dc.date.available2009-10-13T09:06:31Z-
dc.date.issued2001-02-01-
dc.identifier.citationHigh-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. 2001, 19 (3):727-35 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid11157024-
dc.identifier.urihttp://hdl.handle.net/10541/84141-
dc.description.abstractPURPOSE: To assess the outcome of high-dose therapy with autologous stem-cell support in patients with histologic transformation of low-grade follicular non-Hodgkin's lymphoma (NHL) and identify significant prognostic factors, as well as to compare survival of these patients with that of patients with matched low-grade and de novo high- or intermediate-grade NHL undergoing the same procedure. PATIENTS AND METHODS: Fifty patients with transformed low-grade NHL have been reported to the European Bone Marrow Transplant registry. Outcome from high-dose therapy and significant prognostic factors were analyzed. Their survival was also compared with that of 200 patients with matched low-grade NHL and 200 patients with matched de novo high- or intermediate-grade NHL by a case-matched analysis. RESULTS: The procedure-related death rate among the 50 transformed NHL patients was 18%. Overall survival (OS) and progression-free survival (PFS) rates were 51% and 30% at 5 years, respectively. Median PFS time was 13 months. Raised lactate dehydrogenase levels at transformation (P =.0031) was identified as the only adverse significant predictor of PFS on multivariate analysis. A subgroup of patients with residual chemosensitive disease who attained complete remission after high-dose therapy had the best outcome, with an OS at 5 years of 69%. A comparison with matched patients with low-grade disease and with de novo high- or intermediate-grade lymphoma showed no significant difference in OS (P =.939 and P =.438, respectively). CONCLUSION: Patients with chemosensitive transformed lymphoma should be seriously considered for high-dose therapy and autologous stem-cell support.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cell Transplantationen
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshCase-Control Studies-
dc.subject.meshCell Transformation, Neoplastic-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDisease Progression-
dc.subject.meshDisease-Free Survival-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHematopoietic Stem Cell Transplantation-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Follicular-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshSurvival Rate-
dc.titleHigh-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.en
dc.typeArticleen
dc.contributor.departmentDepartment of Hematology, University College Hospital, London, United Kingdom. catherine.williams@christie-tr.nwest.nhs.uken
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.